April 12, 2025 06:00 AM EDT
Weekly

Biotech’s sur­vival guide; What tar­iffs could mean for phar­ma; Con­gress push­es for $15B fed­er­al biotech in­vest­ment; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Wel­come back to End­points Week­ly! This week’s re­cap kicks off with An­drew Dunn’s ex­am­i­na­tion of the biotech play­book for sur­viv­ing mar­ket tur­moil. As for­mer Al­ny­lam …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

A service from the Financial Times